Number Needed to Treat and Cost Per Responder of Janus Kinase Inhibitors Approved for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Japan.

Tatsuya AtsumiEri AsakuraMichio DoiRuta SawantIsao KawaguchiNobuhito SasakiDanny Liew

Published in: Modern rheumatology (2022)

Upadacitinib 15mg was associated with the lowest NNT and CPR among the three JAK inhibitors used in treatment regimens for Japanese patients with moderate-to-severe RA inadequately responsive to csDMARD.

Keyphrases

rheumatoid arthritis
cardiac arrest
disease activity
early onset
high intensity
systemic lupus erythematosus
combination therapy
interstitial lung disease
drug delivery
drug induced